ARGX Stock Overview
A biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
argenx SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €604.96 |
| 52 Week High | €678.21 |
| 52 Week Low | €349.86 |
| Beta | 0.20 |
| 1 Month Change | -6.80% |
| 3 Month Change | -0.37% |
| 1 Year Change | 62.94% |
| 3 Year Change | 95.21% |
| 5 Year Change | 409.05% |
| Change since IPO | 2,530.26% |
Recent News & Updates
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Feb 27argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)
Jan 23Recent updates
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Feb 27argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)
Jan 23Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
Oct 31argenx: Myositis Data Could Add Billions In Value
Sep 25Argenx: Strong Setup For Outperformance In 2025
Jun 28argenx: Innovation Over Losses In Autoimmune Arena
May 07argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Feb 01Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Sep 21Argenx's neuromuscular disorder drug Vyvgart wins approval in EU
Aug 11Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M
Jul 28argenx: A Very Good Start For Vyvgart
May 25argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
Mar 07argenx: Vyvgart's Approval A Key Step For Continued Value Creation
Dec 22argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Nov 30argenx: R&D Day Goes Unnoticed
Aug 23argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
Jun 30Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals
Jun 07Argenx raises ~$1B in global offering
Feb 03argenx to raise $750M in proposed global offering
Feb 01Shareholder Returns
| ARGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.8% | -1.2% | -4.1% |
| 1Y | 62.9% | -5.6% | 6.6% |
Return vs Industry: ARGX exceeded the US Biotechs industry which returned -5.6% over the past year.
Return vs Market: ARGX exceeded the US Market which returned 6.6% over the past year.
Price Volatility
| ARGX volatility | |
|---|---|
| ARGX Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: ARGX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARGX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,148 | Tim Van Hauwermeiren | www.argenx.com |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
argenx SE Fundamentals Summary
| ARGX fundamental statistics | |
|---|---|
| Market cap | US$36.39b |
| Earnings (TTM) | US$833.04m |
| Revenue (TTM) | US$2.25b |
43.7x
P/E Ratio16.2x
P/S RatioIs ARGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARGX income statement (TTM) | |
|---|---|
| Revenue | US$2.25b |
| Cost of Revenue | US$1.21b |
| Gross Profit | US$1.04b |
| Other Expenses | US$208.29m |
| Earnings | US$833.04m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | 13.71 |
| Gross Margin | 46.24% |
| Net Profit Margin | 36.99% |
| Debt/Equity Ratio | 0% |
How did ARGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 22:08 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
argenx SE is covered by 49 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Charles Pitman-King | Barclays |
| Richard Parkes | BNP Paribas Exane |